Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
GSEA analysis GSEA was performed against hallmarks and oncogenic signature gene set MSigDB database v6.2 database with data set ranked from LogFC ( Statistics All in vitro experiments were repeated three independent times with at least technical triplicates
In March 2026, Structure reported 44-week topline data from the ACCESS II Phase 2 study, showing placebo-adjusted weight loss of up to 16.3%, which the company described as the highest efficacy demonstrated among oral GLP-1 receptor agonists at that time point
It is also intended to be used with GLP-1, leading to much higher weight loss rates
Consider switching to tirzepatide If semaglutide, whether compounded or brand-name, is genuinely not producing results after adequate dosing and time, tirzepatide may be worth considering
